Drugs used to treat spasticity

Drugs

Volumn 59, Issue 3, 2000, Pages 487-495

  Kita, Mariko ^a   Goodkin, Donald E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; CLONIDINE; DANTROLENE; DIAZEPAM; GABAPENTIN; TIZANIDINE;

BLEPHAROSPASM; BRADYCARDIA; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TOLERANCE; HUMAN; HYPOTENSION; IMPLANT; MUSCLE WEAKNESS; PHYSIOTHERAPY; REVIEW; SEDATION; SPASTICITY; STRABISMUS;

EID: 0034006988     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059030-00006     Document Type: Review

References (79)

1. 1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago (IL): Year Book Medical Publishers, 1980: 485-94
2. 2. Young RR. Spasticity: a review. Neurology 1994; 44 Suppl. 9: 12S-20S
3. 3. Bormann J. Electrophysiology of Gaba-a and Gaba-b receptor subtypes. Trends Neurol Sci 1988; 11: 112-6
4. 4. Davidoff RA. Antispasticity drugs: mechanism of action. Ann Neurol 1985; 17: 107-17
5. 5. Van Hemet JCJ. A double-blind comparison of baclofen and placebo in patients with spasticity of cerebral origin. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chigaco (IL): Year Book Medical Publishers, 1980
6. 6. Jerusalem F. A double-blind study on the antispastic action of beta-(4-chlorophenyl)-gamma-amino butyric acid in multiple sclerosis, Nervenarzt 1968; 39: 515
7. 7. Jones RF, Burke D, Morasszeky JE, et al. A new agent for the control of spasticity. J Neurol Neurosurg Psychiatry 1970; 33: 464-8
8. 8. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. BMJ 1971; 4: 15-17
9. 9. Basmajan JV. Lioresal (baclofen) treatment of spasticity in multiple sclerosis. Am J Phys Med 1975; 54 (4): 175-7
10. 10. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. Neurology 1976; 441: 446
11. 11. Levine IM, Jossmann PB, DeAngelis V. Lioresal, a new muscle relaxant in the treatment of spasticity: a double blind quantitative evaluation. Dis Nerv Sys 1977; 38: 1011-5
12. 12. Sawa GM, Paty DW. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979; 6(3): 351-4
13. 13. Hinderer SR, Lehman JF, Price R, et al. Spasticity in spinal cord injured persons: quantitative effects of baclofen and placebo treatments. Am J Phys Med Rehabil 1990; 69 (6): 311-7
14. 14. Smith CR, LaRocca NG, Giesser BS, et al. High dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991; 41: 1829-31
15. 15. Pedersen E, Arlien-Soborg P, Mai J. The mode of action of the BAGA derivative baclofen in human spasticity. Acta Neurol Scand 1974; 50: 665-80
16. 16. Milanov IG. Mechanisms of baclofen action on spasticity. Acta Neurol Scand 1992; 85: 305-10
17. 17. Costa E, Guidotti A. Molecular mechanisms in the receptor action of the benzodiazepines. Ann Rev Toxicol 1979; 19: 531-45
18. 18. Schwarz M, Turski L, Janiszewski W, et al. Is the muscle relaxant effect of diazepam in spastic mutant rats mediated through GABA-independent benzodiazepine receptors? Neurosci Lett 1983; 36: 175-80
19. 19. Pedersen E. Clinical assessment and pharmacologic therapy of spasticity. Arch Phys Med Rehabil 1974; 55: 344-54
20. 20. Kendall PH. The use of diazepam in hemiplegia. Ann Phys Med 1964; 7: 225-8
21. 21. Neill RW. Diazepam in the relief of muscle spasm resulting from spinal-cord lesions. Ann Phys Med 1964; Suppl.: 33-8
22. 22. Nathan PW. The action of diazepam in neurological disorders with excessive motor activity. J Neurol Sci 1970; 10: 33-50
23. 23. Corbett M, Frankel HL, Michaelis L. A double-blind cross-over trial of valium in the treatment of spasticity. Paraplegia 1972; 10: 19-22
24. 24. From A, Heltberg A. A double-blind trial with baclofen and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51: 158-66
25. 25. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long term follow-up of baclofen therapy. Pharmatherapeutica 1987; 4 (5): 278-84
26. 26. Cartlidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23: 17-24
27. 27. Mitchell G. Update on multiple sclerosis therapy. Med Clin North Am 1993; 77: 231-49
28. 28. Coward DM. Selective muscle relaxant properties of tizanidine and an examination of its mode of action. Triangle 1981; 20: 151-58
29. 29. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadazole (DS 103 282). Br J Pharmacol 1982; 76: 473-81
30. 30. Newman PM, Nogues M, Newman PK, et al. Tizanidine in the treatment of spasticity. Eur J. Clin Pharmacol 1982; 23: 31-5
31. 31. Delwaide PJ. Electrophysiological testing of spastic patients: it's potential usefulness and limitations. In: Delwaide PJ, Young RR editors. Clinical neurophysiology in spasticity. Amsterdam: Elsevier, 1985: 185-203
32. 32. United Kingdom Tizanidine Study Group. A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused my multiple sclerosis. Neurology 1994; 44 Suppl. 9: 70-9
33. 33. Lapierre Y, Bouchard S, Tansey C, et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 1987; 14: 513-7
34. 34. Nance PW, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 1994; Suppl. 9: 44S-52S
35. 35. Milanov I, Georgiev D. Mechanisms of tizanidine action on spasticity. Acta Neurol Scand 1994; 89: 274-9
36. 36. Bass B, Weinshenker B, Rice GPA, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Sci 1988; 15 (1): 15-9
37. 37. Stein R, Nordal HJ, Oftendal SI, et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75: 190-4
38. 38. Smolenski C, Muff S, Smolenski-Kauts S. A double-blind comparative trial of a new muscle-relaxant, tizanidine (DS102-282) and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981; 7 (6): 374-83
39. 39. Hoorgstraten MC, van der Ploeg RJO, Van der Burg W, et al. Tizanidine versus baclofen in the treatment of multiple sclerosis patients. Acta Neurol Scand 1988; 77: 224-30
40. 40. Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988; 10 (10): 699-708
41. 41. Pagano MA, Ferreiro ME, Herskovits E. Comparative study of tizanidine and baclofen in patients with chronic spasticity. Rev Neurol Argent 1988; 14 (4): 268-76
42. 42. Rinne UK. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res 1980 Dec 1; 28 (6): 827-36
43. 43. Bes A, Eyssette M, Pierrot-Deseilligny E, et al. A multi-centre, double-blind trial of tizanidine, a new anti-spastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988; 10: 709-18
44. 44. Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989; 4: 296-301
45. 45. Dall JT, Harmon RL, Quinn CM. Use of clonidine for treatment of spasticity arising from various forms of brain injury: a case series. Brain Injury 1996; 10 (6): 453-8
46. 46. Donovan WH, Carter RE, Rossi CD, et al. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988; 69 (3 Pt 1): 193-4
47. 47. Herman R, Mayer N, Mecomber SA. Clinical pharmaco-physiology of dantrolene sodium. Am J Physical Med 1972; 51: 296-311
48. 48. Ellis KO, Carpenter JF. Mechanisms of control of skeletal muscle contraction by dantrolene sodium. Arch Phys Med Rehabil 1974; 55: 362-9
49. 49. Pinder RM, Brodgen RN, Speight TM, et al. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977; 13: 3-23
50. 50. Whyte J, Robinson KM. Pharmacologic management. In: Glenn M, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia (PA): Lea & Febiger, 1990: 201-26
51. 51. Monster AW, Tamai Y, McHenry J. Dantrolene sodium in spasticity. Acta Neurol Scand 1979; 59: 309-16
52. 52. Gelenberg AJ, Poskanzer DC. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23: 1313-5
53. 53. Tolosa ES, Soli RW, Loewenson R. Treatment of spasticity in multiple sclerosis with dantrolene. JAMA 1975; 233 (10): 1046
54. 54. Katrak PH, Cole A, Poulos CJ, et al. Objective assessment of spasticity, strength and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil 1992; 73: 4-9
55. 55. Schmidt RT, Lee RH, Spehlman R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976; 39: 350-6
56. 56. Nogen AG. Medical treatment for spasticity in children with cerebral palsy. Child's Brain 1976; 2: 304-8
57. 57. Glass A, Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia 1974; 12: 170-4
58. 58. US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilep Res, 1994 May, 18 (1): 67-73
59. 59. Fromm GH. Gabapentin. Epilepsia 1994; 35 Suppl. 5: 77-80S
60. 60. McLean MJ. Gabapentin. Epilepsia 1995; 36 Suppl. 2: 73S-86S
61. 61. Priebe MM, Sherwood AM, Graves DE, et al. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997; 35: 171-5
62. 62. Dunevsky A, Perel A. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehabil 1998; 77: 451-4
63. 63. Yablon SA, Agana BT, Ivanhoe CB, et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open label trial. Neurology 1996; 47: 939-44
64. 64. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-10
65. 65. Burbaud P, Wiart L, Dubos JL, et al. A randomized, double blind placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265-9
66. 66. Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989; 65: 208-10
67. 67. Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512-5
68. 68. Cosgrove AP, Corry IS, Graham HK. Botulinium toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36 (5): 386-96
69. 69. Roman LA, Mooney III JF, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14 (3): 299-303
70. 70. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-21
71. 71. Ashworth B. Preliminary trial of carisprodol in multiple sclerosis. Practitioner 1964; 192: 540-2
72. 72. Lee KC, Carson L, Kinnin E, et al. The Ashworth Scale: a reliable and reproducible method of measuring spasticity. J Neuro Rehab 1989; 3: 205-9
73. 73. Ochs G, Struppler A, Meyerson BA, et al. Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatry 1989; 52: 933-9
74. 74. Albright AL, Barron WB, Fasick MP, et al. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 1993; 270: 2475-7
75. 75. Dralle D, Muller H, Zierski J, et al. Intrathecal baclofen for spasticity [letter]. Lancet 1985; II 8462: 1003
76. 76. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years experience. J Neurosurg 1992; 77: 236-40
77. 77. Nance PW, Schryvers OI, Schmidt BJ, et al. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admission. Can J Neurol Sci 1995; 22: 122-9
78. 78. Nanninga JB, Frost F, Penn R. Effect of intrathecal baclofen on bladder and sphincter function. J Urol 1989; 142: 101-5
79. 79. Siegfried J, Rea GL. Intrathecal application of drugs for muscle hypertonus. Scand J Rehab Med 1988; 17 Suppl.: 145-8